Cover ImageSALE
市場調查報告書

流感疫苗的全球市場:2018年∼2022年

Global Influenza Vaccine Market 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 599704
出版日期 內容資訊 英文 113 Pages
訂單完成後即時交付
價格
Back to Top
流感疫苗的全球市場:2018年∼2022年 Global Influenza Vaccine Market 2018-2022
出版日期: 2018年01月09日 內容資訊: 英文 113 Pages
簡介

關於流感疫苗

流感是由流感病毒引起的傳染病。流感病毒是屬於正粘病毒科的核糖核酸(RNA)病毒,一種螺旋形的單鏈病毒。A型流感病毒影響所有年齡群組並導致中度至重度疾病,而由B型流感病毒引起的感染導致疾病輕微並主要影響兒童。C型流感很少導致人類疾病,因此不會引起流行病。流感已成為全球嚴重的健康問題。市場包括用於預防流感的弱毒化活病毒疫苗和重組流感疫苗。導致市場成長的有每年的疫苗接種與政府的舉措提升意識的必要性。

Technavio的分析師預測,從2018年到2222年期間,全球流感疫苗市場將以7.23%的年複合成長率成長。

本報告提供全球流感疫苗市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 簡介

  • 市場概要

第5章 市場情形

  • 市場生態系統
  • 市場特性
  • 市場區隔分析

第6章 市場規模

  • 市場定義
  • 市場規模:2017年
  • 市場規模及預測:2017-2022年

第7章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭的威脅
  • 市場情形

第8章 開發平台形勢

第9章 市場區隔:各疫苗類型

  • 概要
  • 各疫苗類型比較
  • 弱毒化流感疫苗市場
  • 重組流感疫苗市場
  • 市場機會:各疫苗類型

第10章 市場區隔:各年齡

  • 大人
  • 小兒科

第11章 客戶形勢

第12章 地區形勢

  • 地理市場區隔
  • 地區比較
  • 南北美洲
  • 歐洲、中東、非洲地區
  • 亞太地區
  • 市場機會

第13章 決策架構

第14章 成長要素與課題

  • 市場成長要素
  • 市場課題

第15章 市場趨勢

  • 強力的開發平台
  • 策略性聯盟

第16章 業者情勢

  • 概要
  • 創造性破壞

第17章 供應商分析

  • 概要
  • 供應商的分類
  • 供應商的市場定位
  • AstraZeneca
  • CSL
  • GlaxoSmithKline
  • Sanofi

第18章 附錄

  • 簡稱清單
目錄
Product Code: IRTNTR20289

About Influenza Vaccine

Influenza is an infectious disease caused by the influenza virus. It is also known as flu. Influenza virus is a ribonucleic acid (RNA) virus that belongs to Orthomyxoviridae family. It is a helical shaped, single-stranded virus. Influenza A virus affects people of all age groups and causes moderate to severe illness, while the infection due to influenza B virus results in milder disease and affects pediatrics primarily. Human illness due to influenza C is rare. Influenza C illness might be due to subclinical cases. Hence, it does not cause epidemic diseases. Influenza has emerged as a severe health concern globally. The market encompasses both live attenuated as well as recombinant influenza vaccines for the prevention of influenza. The major factors that lead to the market growth include the need for annual vaccination and government initiatives to improve awareness about vaccination.

Technavio's analysts forecast the global influenza vaccine market to grow at a CAGR of 7.23% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global influenza vaccine market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of influenza vaccine.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Influenza Vaccine Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • CSL
  • GlaxoSmithKline
  • Sanofi

Other Prominent Vendors

  • Altimmune
  • BionVax
  • FluGen
  • FOLIA BIOTECH
  • Genentech
  • Green Cross
  • Medicago
  • Moderna Therapeutics
  • Novavax
  • Shijiazhuang Yiling Pharmaceutical
  • SK Chemicals
  • UNM Pharma
  • Vaccitech
  • Vaxart
  • Vaxine Pty
  • Visterra.

Market driver

  • Rising awareness about influenza vaccination
  • For a full, detailed list, view our report

Market trend

  • Development of strong pipeline
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: PIPELINE LANDSCAPE

PART 09: MARKET SEGMENTATION BY VACCINE TYPE

  • Overview
  • Comparison by vaccine type
  • Global live attenuated influenza vaccines market
  • Global recombinant influenza vaccines market
  • Market opportunity by vaccine type

PART 10: MARKET SEGMENTATION BY AGE GROUP

  • Adults
  • Pediatrics

PART 11: CUSTOMER LANDSCAPE

PART 12: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Influenza vaccine market in Americas
  • Influenza vaccine market in EMEA
  • Influenza vaccine market in APAC
  • Market opportunity

PART 13: DECISION FRAMEWORK

PART 14: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 15: MARKET TRENDS

  • Strong pipeline
  • Strategic alliances

PART 16: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 17: VENDOR ANALYSIS

  • Overview
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • CSL
  • GlaxoSmithKline
  • Sanofi

PART 18: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global vaccine market: Segmentation
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition: Inclusions and exclusions checklist
  • Exhibit 06: Market size 2017
  • Exhibit 07: Validation techniques employed for market sizing 2017
  • Exhibit 08: Global influenza vaccine market 2017-2022 ($ millions)
  • Exhibit 09: Global influenza vaccine market: Year-over-year growth 2018-2022 (%)
  • Exhibit 10: Five forces analysis 2017
  • Exhibit 11: Five forces analysis 2022
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition: Five forces 2017
  • Exhibit 18: Pipeline landscape by development phase
  • Exhibit 19: Key clinical trials candidates of influenza vaccines
  • Exhibit 20: Global influenza vaccine market by vaccine type 2017-2022 (%)
  • Exhibit 21: Comparison by vaccine type
  • Exhibit 22: Global live attenuated influenza vaccines market 2017-2022 ($ millions)
  • Exhibit 23: Global live attenuated influenza vaccines market: Year-over-year growth 2018-2022 (%)
  • Exhibit 24: Global recombinant influenza vaccines market 2017-2022 ($ millions)
  • Exhibit 25: Global recombinant influenza vaccines market: Year-over-year growth 2018-2022 (%)
  • Exhibit 26: Market opportunity by vaccine type
  • Exhibit 27: Adult influenza vaccine products and their cost
  • Exhibit 28: Pediatric influenza vaccine products and their cost
  • Exhibit 29: Customer landscape
  • Exhibit 30: Global influenza vaccine market by geography 2017-2022 (%)
  • Exhibit 31: Regional comparison
  • Exhibit 32: Influenza vaccine market in Americas 2017-2022 ($ millions)
  • Exhibit 33: Influenza vaccine market in Americas: Year-over-year growth 2018-2022 (%)
  • Exhibit 34: Top 3 countries in Americas
  • Exhibit 35: Influenza vaccine market in EMEA 2017-2022 ($ millions)
  • Exhibit 36: Influenza vaccine market in EMEA: Year-over-year growth 2018-2022 (%)
  • Exhibit 37: Top 3 countries in EMEA
  • Exhibit 38: Influenza vaccine market in APAC 2017-2022 ($ millions)
  • Exhibit 39: Influenza vaccine market in APAC: Year-over-year growth 2018-2022 (%)
  • Exhibit 40: Top 3 countries in APAC
  • Exhibit 41: Market opportunity
  • Exhibit 42: Distribution of influenza vaccine doses in US by season
  • Exhibit 43: Steps for production of IIV
  • Exhibit 44: Molecules in phase III with sponsors
  • Exhibit 45: Vendor landscape
  • Exhibit 46: Landscape disruption
  • Exhibit 47: Vendor landscape
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: AstraZeneca: Overview
  • Exhibit 51: AstraZeneca: Business segments
  • Exhibit 52: AstraZeneca: Organizational developments
  • Exhibit 53: AstraZeneca: Geographic focus
  • Exhibit 54: AstraZeneca: Segment focus
  • Exhibit 55: AstraZeneca: Key offerings
  • Exhibit 56: AstraZeneca: Key customers
  • Exhibit 57: CSL: Overview
  • Exhibit 58: CSL: Business segments
  • Exhibit 59: CSL: Organizational developments
  • Exhibit 60: CSL: Geographic focus
  • Exhibit 61: CSL: Segment focus
  • Exhibit 62: CSL: Key offerings
  • Exhibit 63: CSL: Key customers
  • Exhibit 64: GlaxoSmithKline: Overview
  • Exhibit 65: GlaxoSmithKline: Business segments
  • Exhibit 66: GlaxoSmithKline: Organizational developments
  • Exhibit 67: GlaxoSmithKline: Geographic focus
  • Exhibit 68: GlaxoSmithKline: Segment focus
  • Exhibit 69: GlaxoSmithKline: Key offerings
  • Exhibit 70: GlaxoSmithKline: Key customers
  • Exhibit 71: Sanofi: Overview
  • Exhibit 72: Sanofi: Business segments
  • Exhibit 73: Sanofi: Organizational developments
  • Exhibit 74: Sanofi: Geographic focus
  • Exhibit 75: Sanofi: Segment focus
  • Exhibit 76: Sanofi: Key offerings
  • Exhibit 77: Sanofi: Key customers
Back to Top